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 INTRODUCTION 
 Acute febrile illnesses comprise the majority of the disease 
burden to most populations in sub-Saharan Africa. 1, 2 Although 
a considerable percentage of these syndromes is attributable 
to familiar diseases such as malaria and typhoid fever, recent 
studies suggest that malaria may be overdiagnosed and that 
a significant proportion of febrile diseases may be caused by 
pathogens not frequently considered in most settings in sub-
Saharan Africa. 3– 6 
 Arboviruses in West Africa include members of the genera 
 Flavivirus [yellow fever (YFV), dengue (DENV), and West Nile 
(WNV)],  Alphavirus [chikungunya (CHIKV) and O’nyong 
nyong (ONNV)],  Phlebovirus [Rift Valley Fever (RVFV)], and 
 Bunyavirus [Tahyna (TAHV)]. Evidence and reason suggest 
that these and other arboviruses circulate frequently in sub-
Saharan Africa: competent mosquito vectors for many arbovi-
ruses are found throughout the region, the incidence of other 
mosquito-borne illnesses is generally high, and outbreaks of 
YFV, CHIKV, and other arboviruses are periodically noted. 
Whereas large outbreaks often initiate more active epidemio-
logic investigation and attempts at laboratory diagnosis, identi-
fication of arboviral syndromes on a daily basis in sub-Saharan 
Africa is rare. Detection is hampered by the non-specific clini-
cal presentation, lack of local laboratory diagnostic facilities, 
cross-reactions on serologic testing, and passive and inconsis-
tent surveillance in most African countries. 7 The reported and 
confirmed cases of arbovirus infection are thought to repre-
sent only a small percentage of the actual cases. 8, 9 Without the 
possibility for laboratory confirmation, many clinicians’ index 
of suspicion to diagnosis of arboviral syndromes is low. 
 The Republic of Guinea is located on the Atlantic coast of 
West Africa, with a population of approximately 9.9 million. 
Evidence points to the circulation of various arboviruses in 
Guinea: outbreaks of YFV have occurred almost biannually 
since 2000 in various parts of the country, including northwest-
ern Guinea (2000) and the towns of Conakry and N’Zérékoré 
(2001), Macenta (2003), and Faranah (2005) ( Figure 1 ). 10 The 
largest YFV outbreak reported in Africa was in Conakry in 
2000–2001. 11 A serosurvey of febrile patients between 1978 
and 1989 found that 40% were positive for YFV by hemag-
glutination assay. 12 Serological surveys have also showed 
antibodies to CHIKV in Guinea, although the morbidity asso-
ciated with infection has not been thoroughly investigated 12– 14 
(E. Jentes, unpublished data). Furthermore, a host of arbo-
viruses have been isolated from arthropods, bats, birds, non-
human primates, and rarely, humans in Guinea, although, with 
the exception of YFV, the incidence of human infection and 
disease due to arboviruses has not been reported nor sys-
tematically sought in that country. 12, 13, 15– 22 We hypothesized 
that arboviruses accounted for a considerable proportion of 
undiagnosed febrile illnesses in Guinea and sought to deter-
mine the frequency of human arboviral disease in two hospi-
tals in two ecologically distinct regions of Guinea. The original 
intention was to conduct a matched case-control study over 1 
year and establish diagnostics for arboviruses at the Center 
International de Recherche sur les Infections Tropicale in 
N’Zérékoré, Guinea. However, civil unrest, including nation-
wide strikes (including hospital staff), street violence, and gas 
shortages, forced closure of the study after just a few months. 
Nevertheless, the limited data that were collected and are 
reported here provide valuable information on the frequency 
and diversity of arbovirus infections in Guinea. 
 METHODS AND MATERIALS 
 Study area.  Despite its abundant natural resources, including 
30% of the world’s bauxite reserves, Guinea remains one of 
the least developed countries in the world. Similar to many 
other sub-Saharan African nations, only 5.3% of the gross 
national product is spent on health. Agriculture, which is 
approximately 25% of the gross domestic product nationally, 
includes cultivation of rice, bananas, sweet potatoes, timber, 
and coffee. The average yearly temperature is 25.4°C, with 
average yearly rainfall of around 1,700 mm. There are single 
rainy and dry seasons extending from June to November and 
December to May, respectively. 
 Guinea is divided roughly into four distinct geographic and 
administrative regions: Basse Côte (lowlands near the oceanic 
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coast), Fouta Djalon (mountainous middle region), Haute-
Guinée (northeast savannah), and Guinée Forestière (south-
eastern rainforest). This study was conducted in the towns 
of N’Zérékoré and Faranah ( Figure 1 ). Faranah (population 
of 88,000) is located in the savannah region (Haute-Guinée) 
along the Niger River basin, whereas N’Zérékoré (population 
of 120,000) is in an area of secondary tropical forest (Guinée 
Forestière) with interspersed agricultural plots. As in sur-
rounding Liberia, Côte d’Ivoire, and Sierra Leone, Guinée 
Forestière has now been significantly deforested, leaving 
mainly palm and banana trees in areas that were previously 
dense with primary tropical forest. 
 Human subject selection.  The study was approved by the 
Tulane University Internal Review Board and the Ethics 
Committee of the Guinean Ministry of Health. Patients who 
met a broad case definition for suspected acute febrile viral 
diseases were recruited from N’Zérékoré Regional Hospital 
(NZRH) and Faranah Regional Hospital (FRH) ( Table 1 ). 
Patients were informed about the study, and oral consent 
was obtained before inclusion in the study. Because these 
hospitals charge for services on a sliding economic scale 
and are the reference centers for their respective regions, 
they are visited by people of all socio-economic levels from 
the town and surrounding prefecture and thus, have large 
catchment areas. NZRH has 175 beds, and FRH has 100 beds. 
Both hospitals provide services in general medicine as well 
as pediatric, maternity, and surgical wards and ambulatory 
services. Subjects were enrolled from August 2006 until civil 
unrest forced early termination of the study in January 2007. 
The study was initiated in August to correspond with the 
middle of the rainy season in Guinea, because the majority 
of cases of YFV in West Africa are noted from the middle of 
the rainy season to the middle of the dry season. 7 The original 
intention of obtaining matched controls for each subject 
to investigate and compare risk factors for arbovirus infection 
in the community was not possible given the civil unrest. 
 Specimen collection.  After explaining the objectives of the 
study and obtaining informed consent, 5 mL of blood were 
taken through venipuncture in red-top Vacutainer tubes 
(Becton, Dickinson, and Company, Franklin Lakes, NJ) from 
each subject at enrollment, which was usually on the first day 
of hospitalization (acute), and again on days 7 (late acute) and 
28 after hospitalization (convalescent). However, for reasons 
of both subject adherence and civil unrest, we were often 
unable to obtain a complete set of three blood samples from 
each subject (see below). Because Lassa virus, a biosafety 
level-4 agent, is endemic in the area of study, all samples were 
inactivated by heating (56°C for 30 minutes) before further 
manipulation. 23 This protocol has since been changed to 
60°C for 60 minutes. The serum was separated from the clot 
by centrifugation and stored in labeled cryovials in a solar-
powered freezer (approximately −11°C) until testing. 
 Laboratory analysis.  All serum samples were first tested in 
Guinea by YFV immunoglobulin M (IgM) antibody capture 
(MAC) enzyme-linked immunosorbent assay (ELISA) and 
PanBio DEN IgM ELISA (PanBio Ltd, Brisbane, Australia ) 
following the Centers of Disease Control and Prevention 
(CDC) Clinical Laboratory Improvement Amendments 
(CLIA)- approved protocol and manufacturer’s instructions, 
respectively. 24, 25 When the deteriorating civil situation made it 
clear that the study must be terminated, the serum samples 
were transported on cold packs over land to Sierra Leone and 
subsequently, to Côte d’Ivoire, where they were shipped on 
dry ice to Tulane University in New Orleans, LA. Finally, they 
were shipped overnight to the Arboviral Diseases Branch 
of the CDC in Fort Collins, CO. At CDC, the samples were 
tested by MAC ELISA against a standard African antigen 
panel that includes WNV, YFV, DENV (serotype 2), CHIKV, 
and TAHV. 25 Samples with positive or equivocal IgM results 
were confirmed by virus-specific neutralizing antibody titer 
90% endpoint plaque-reduction neutralization assay (PRNT) 
in Vero cells using a 0.5% agarose double overlay visualized 
with neutral red staining in the second overlay. 26, 27 Neutralizing 
antibody titers were determined using PRNT 90% cutoff values 
for confirmation of IgM positive and equivocal samples. 28, 29 
Neutralizing antibody titer is expressed as the reciprocal of 
the endpoint serum dilution that reduced the challenge virus 
plaque count by 90% based on the back titration. Samples 
were confirmed as positive with a positive or equivocal IgM 
and ≥ 4-fold neutralizing titer difference between paired 
 Figure 1 . Guinea and surrounding countries in West Africa. 
The four defined topographical regions of Guinea are demarcated. 
Epicenters of YFV outbreaks in Guinea since 2000 are signified by 
stars. The study described here took place in N’Zérékoré (Forest 
Region) and Faranah (Savannah Region). 
 Table 1 
Case definition used to detect patients with suspected acute febrile 
viral diseases at N’Zérékoré and Faranah Regional Hospitals * 
Major signs Minor signs
Abnormal bleeding (from the mouth, 












Edema of the neck and/or face




Buzzing in the ears or acute deafness
Persistent hypotension
Elevated liver transaminases 
(serum glutamic oxaloacetic 
transaminase [SGOT]/aspartate 
aminotransferase [AST] )
 * For inclusion in the study, the patient must present with fever > 38°C for less than 3 weeks, 
absence of signs of local inflammation (i.e., the illness is systemic), negative thick smear for 
malaria, absence of a clinical response after 48 hours of antimalaria treatment and/or broad-
spectrum antibiotics, and two major signs or one major sign and two minor signs. Common 
antimalarial drugs used in the area include chloroquine, quinine, sulfadoxine/pyrimethamine, 
and artemisinin compounds. Common antibiotic regimens include combinations of vari-
ous beta-lactams, including penicillin derivatives and cephalosporins, aminoglycosides, sulfa 
drugs, macrolides, and chloramphenicol. 
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specimens or between antibody titer to one virus over another, 
such as DENV and YFV. Those samples in which there was no 
neutralizing antibody titer or those that had less than a 4-fold 
difference in titer were classified as presumptive. 
 Data were recorded by hand on case-report forms and 
subsequently, were entered into electronic spreadsheets 
and imported into SPSS Statistics version 17.0 (SPSS, Inc., 
Chicago, IL) for statistical analysis. χ 2 , Yates’ χ 2 , Fisher’s exact, 
and Student’s  t tests were used as appropriate. 
 RESULTS 
 Forty-seven subjects were enrolled ( Table 2 ). In 74% (35/47) 
of cases, only an acute sample was collected; in 37% (10/47), an 
acute and late acute sample were obtained, and in 4% (2/47), 
acute, late acute, and convalescent samples were obtained. 
There were no significant demographic differences between 
the patients enrolled at the two hospitals. 
 All 47 subjects tested negative for YFV or DENV infec-
tion by the MAC ELISAs performed in Guinea. However, 
based on the results of the tests conducted at CDC, arbovi-
rus infections were considered confirmed or presumptive 
in 63% (30/47) of the subjects, 14 from N’Zérékoré and 16 
from Faranah ( Table 3 ). Infected patients were significantly 
younger than uninfected ones (33 versus 47 years, respec-
tively;  P = 0.009). Females (17/20; 85%) were more likely to 
be infected than males (13/27; 48%);  P = 0.014); 14 (70%) of 
20 women in the study were housewives, 13 (93%) of which 
were positive. There was no apparent geographic clustering of 
cases, with positives from 17 different villages (7 in and around 
N’Zérékoré and 10 in and around Faranah). Only 3 (10%) of 
30 positive persons reported traveling outside their village in 
the 10 days before illness, suggesting that most, if not all, infec-
tions were acquired locally. Infections seemed to be roughly 
evenly dispersed across the various ethnic groups studied, 
with cases in 10 of 12 different groups represented in the study 
( Table 2 ). There was no association with marital status or the 
number of people living in the house. 
 Flavivirus infections, especially WNV, predominated, but 
infections were noted with viruses from all three genera tested 
( Table 3 ). In three cases, there was evidence of coinfection by 
two arboviruses: one TAHV/CHIKV, one WNV/CHIKV, and 
one CHIKV with another untypeable bunyavirus (this patient 
was positive on the ELISA IgM for Tahyna virus but was 
PRNT negative, presumably indicating infection with a differ-
ent bunyavirus). No samples showed evidence of coinfection 
by viruses of the same genus. 
 The civil unrest often prevented physicians from coming to 
the hospital to make detailed clinical observations. Addition-
ally, dates of onset were not reliably recorded. However, we 
were able to record the patients’ self-reported symptoms, 
which tended to be very non-specific ( Table 4 ). There were no 
statistical differences in symptoms between patients with and 
without arbovirus infection or between patients with specific 
arbovirus infections, although the small sample size in each 
virus category precluded meaningful statistical analysis. Vital 
signs taken on admission did not vary significantly between 
 Table 2 
Demographic findings of 47 patients presenting with suspected acute 
febrile viral diseases to N’Zérékoré (NZRH) and Faranah (FRH) 




Number of subjects enrolled 24 23 47
Sex † 
Male 15 (63) 12 (52) 27 (57)
Female 9 (37) 11 (48) 20 (43)
Age (years) † 
≤ 20 6 (25) 1 (4) 7 (15)
21–40 12 (50) 14 (61) 26 (55)
41–60 3 (12.5) 5 (22) 8 (17)
≥ 61 3 (12.5) 3 (13) 5 (13)
Profession † 
Housewife 7 (29) 7 (30) 14 (30)
Farmer 4 (17) 9 (39) 13 (28)
Merchant 5 (21) 0 (0) 5 (11)
Student 4 (17) 0 (0) 4 (9)
Driver 2 (8) 1 (4) 3 (6)
Other 2 (8) 6 (26) 8 (17)
Ethnicity ‡ 
Malinké 8 (35) 11 (48) 19 (41)
Peuhl 3 (13) 6 (26) 9 (20)
Konianké 5 (22) 0 (0) 5 (11)
Guerzé 3 (13) 1 (4) 4 (9)
Kissi 1 (4) 1 (4) 2 (4)
Soussou 1 (4) 0 (4) 1 (2)
Other 2 (9) 4 (17) 6 (13)
 NZRH = N’Zérékoré Regional Hospital; FRH = Faranah Regional Hospital. 
 *  Percentages may not add up to 100% because of rounding. 
 † There was no significant difference in the sexes (χ 2 = 0.5,  P = 0.47), ages ( t test = 0.13,  P = 
0.90), professions (housewife, farmer vs. all other categories; χ 2 = 3.7,  P = 0.16), and ethnicities 
(Malinké, Peuhl vs. all other categories; Yates’ χ 2 = 2.0,  P = 0.36) of patients between NZRH 
and FRH. Categories were collapsed for statistical comparison because of small sample size; 
however, all categories are shown in the table for descriptive purposes. 
 ‡  Ethnicity missing for one patient from NZRH. 
 Table 3 
Results of ELISA and PRNTs for a standard panel of African arbo-
viruses on 47 patients presenting with suspected acute febrile viral 
diseases to N’Zérékoré Regional Hospital (NZRH) and Faranah 






(% tested) * 
FRH 
(% tested) * 
Flaviviruses
Yellow fever
Confirmed † 0 (0) 1 (4) 1 (2)
Presumptive † 0 (0) 1 (4) 1 (2)
West Nile
Confirmed 1 (4) 1 (4) 2 (4)
Presumptive 8 (33) 1 (4) 9 (19)
Dengue
Confirmed 0 (0) 1 (4) 1 (2)
Presumptive 0 (0) 0 (0) 0 (0)
Alphaviruses
Chikungunya
Confirmed 1 (4) 3 (13) 4 (9)
Presumptive 1 (4) 3 (13) 4 (9)
Bunyaviruses
Tahyna
Confirmed 1 (4) 0 (0) 1 (2)
Presumptive 2 (8) 2 (9) 4 (9)
Multiple infections
Tahyna confirmed/
chikungunya presumptive 0 (0) 1 (4) 1 (2)
West Nile confirmed/
chikungunya presumptive 1 (4) 0 (0) 1 (2)
Chikungunya 
confirmed/presumptive 
non-Tahyna bunyavirus 1 (4) 0 (0) 1 (2)
Negative 8 (33) 9 (39) 17 (36)
Total 24 23 47
 *  Percentages may not add up to 100% because of rounding. 
 †  See Methods and Materials for definition of confirmed and presumptive cases. 
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those with and without arbovirus infection, with the excep-
tion of the temperature (38.1°C and 37.3°C, respectively;  P = 
0.002). One patient with confirmed YFV infection reported a 
spontaneous abortion at home before coming to the hospital. 
Two patients died: one positive for DENV and the other with 
a presumptive diagnosis of TAHV infection. 
 DISCUSSION 
 Despite the brief surveillance period and unanticipated 
logistical impediments encountered in our study, over 60% 
of the patients that we sampled in two ecologically distinct 
regions of Guinea had evidence of arboviral syndromes. Five 
distinct arbovirus infections were noted. With the exception 
of yellow fever, these are the first reported cases of human 
disease caused by these viruses in Guinea to our knowledge. 
These results strongly suggest that various arboviruses circu-
late, are common causes of human disease in Guinea, and are 
likely to be markedly underdiagnosed. 
 Perhaps the least surprising finding of our study is identi-
fication of cases of YFV as YFV is endemic in sub-Saharan 
Africa. 10 Despite a safe and effective vaccine, cases of YFV 
infection were reported in 13 of 14 West African countries 
at risk from 2000 to 2006, including numerous outbreaks in 
Guinea ( Figure 1 ), although there was no recognized outbreak 
of YFV or any other arbovirus in Guinea during the period of 
our study. 10, 11, 30, 31 It should be noted that only two of the sub-
jects in our study reported having received the YFV vaccine—
one CHIKV case from FRH and one case who was negative 
for all viruses tested. Ten subjects reported never receiving 
YFV vaccine. Thirty-five subjects did not know their vacci-
nation status, including the two positive for anti-YFV IgM 
antibody. The resurgence of YFV in West Africa is partially 
attributable to the end of the routine preventative immuniza-
tion campaigns common during the colonial era, which ended 
in the late 1950s/early 1960s; however, many African coun-
tries, including Guinea, have added YFV vaccine to the rec-
ommended list of routine childhood vaccines. 30 
 Our finding of two cases of YFV during such a brief period 
of more intensive surveillance suggests that YFV infection 
may be more common that typically noted or assumed. We 
suspect that more thorough surveillance, at least in rural areas, 
would show a baseline incidence of YFV infection that is 
> 0. Such a finding would have significant consequences given 
the present policy of implementing costly and labor-intensive 
mass vaccination campaigns based on the confirmation of a 
single case. Declaration of an outbreak should ideally take 
into account the level of baseline transmission, but such an 
approach will require markedly enhancing surveillance and 
laboratory capacity. 
 CHIKV infection was frequent in our study (17% of cases), 
a finding in keeping with previous reports from Guinea 
 Table 4 
Self-reported symptoms in patients with suspected arbovirus infections presenting to N’Zérékoré and Faranah Regional Hospitals 
Symptom
Number reporting (%)
All patients Positive for any virus * 
Flavivirus positive † Alphavirus positive * Bunyavirus positive * 
YFV WNV CHIKV TAHV
Fever ‡ 42/44 (96) 26/28 (93) 2/2 (100) 11/11 (100) 11/11 (100) 4/5 (80)
Malaise 42/44 (96) 26/28 (93) 0/1 (−) 12/12 (100) 10/11 (91) 6/6 (100)
Headache 38/45 (84) 23/29 (79) 0/1 (−) 10/12 (83) 11/11 (100) 4/6 (67)
Light-headedness 35/44 (80) 20/28 (71) 0/1 (−) 9/12 (75) 9/10 (90) 4/6 (67)
Muscle aches 34/44 (77) 22/28 (79) 1/1 (100) 11/12 (92) 7/11 (64) 4/6 (67)
Nausea/vomiting 34/45 (76) 23/28 (82) 1/2 (50) 10/12 (83) 9/10 (90) 5/6 (83)
Abdominal pain 30/42 (71) 18/25 (72) 2/2 (100) 9/12 (75) 5/7 (71) 4/6 (67)
Joint pain 30/44 (68) 19/28 (68) 0/1 (−) 10/12 (83) 6/11 (55) 5/6 (83)
Back pain 29/44 (66) 19/28 (68) 0/1 (−) 9/12 (75) 8/11 (73) 3/6 (50)
Cough 26/42 (62) 17/26 (65) 1/1 (100) 8/11 (73) 7/10 (70) 2/6 (33)
Shortness of breath 27/44 (61) 17/27 (63) 1/1 (100) 9/12 (75) 6/9 (67) 4/6 (67)
Chest pain 24/42 (57) 17/26 (65) 1/1 (100) 9/12 (75) 5/9 (56) 3/6 (50)
Epigastric pain 24/43 (56) 15/26 (58) 1/2 (50) 8/12 (67) 5/8 (63) 2/6 (33)
Diarrhea 23/44 (52) 14/27 (52) 2/2 (100) 8/12 (67) 3/9 (33) 3/6 (50)
Yellow eyes/jaundice 17/36 (47) 12/23 (52) 0/1 (−) 4/10 (40) 5/9 (56) 3/5 (60)
Ringing in the ears 14/40 (35) 9/25 (36) 0/1 (−) 5/10 (50) 4/10 (40) 1/6 (17)
Sore throat 13/39 (33) 8/23 (35) 0/1 (−) 5/10 (50) 2/8 (25) 2/6 (50)
Nasal congestion 12/41 (29) 9/25 (36) 0/1 (−) 7/12 (58) 2/8 (25) 1/6 (17)
Gum/oral bleeding 10/44 (23) 8/26 (31) 2/2 (100) 5/12 (42) 1/9 (11) 1/6 (17)
Red eyes/conjunctivitis 7/39 (18) 6/23 (26) 0/1 (−) 3/10 (30) 2/8 (25) 1/6 (17)
Facial or neck swelling 7/43 (16) 6/27 (22) 0/1 (−) 40/11 (36) 2/11 (18) 1/6 (17)
Vomiting blood/hematemesis 7/44 (16) 6/27 (22) 1/2 (50) 1/12 (8) 3/9 (33) 1/6 (17)
Nose bleeds/epistaxis 7/43 (16) 5/26 (19) 2/2 (100) 3/12 (25) 2/8 (25) 0/6 (−)
Bloody or black stools/melena 6/44 (14) 4/27 (15) 1/2 (50) 1/12 (8) 1/9 (11) 1/6 (17)
Mouth ulcers 4/42 (10) 3/26 (12) 0/1 (−) 2/11 (18) 2/10 (20) 0/6 (−)
Hearing loss 4/42 (10) 2/22 (9) 0/1 (−) 2/9 (22) 0/8 (−) 0/6 (−)
Swollen lymph nodes 3/43 (7) 3/27 (11) 0/1 (−) 3/11 (27) 1/11 (9) 0/6 (−)
Rash 2/41 (5) 2/25 (8) 0/1 (−) 2/10 (20) 1/10 (10) 0/6 (−)
Vaginal bleeding 2/41 (5) 2/26 (8) 1/2 (50) § 1/12 (8) 0/8 (−) 0/6 (−)
Bloody urine 1/42 (2) 1/26 (4) 1/2 (50) 0/11 (−) 0/9 (−) 0/6 (−)
 CHIKV = chikungunya virus; DENV = dengue virus; TAHV = Tahyna virus; WNV = West Nile virus; YFV = yellow fever virus. 
 *  Includes both confirmed and presumptive cases. 
 † The one person positive for DENV was unconscious on admission and subsequently died. No information was available on symptoms at disease onset. 
 ‡  In two cases, patients reported fever > 38°C for less than 3 weeks but were afebrile on presentation to the hospital. 
 § The patient reported a spontaneous abortion before coming to the hospital. 
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showing a seroprevalence of CHIKV antibody over 50% 13 
(E. Jentes, unpublished data). There are also numerous reports 
of CHIKV isolations from various arthropods and small mam-
mals in Guinea. 12, 15, 32 The geographic distribution of CHIKV 
virus includes most of sub-Saharan Africa, although the virus 
has not frequently been the subject of study in West Africa. 33– 36 
CHIKV is considered endemic in most rural areas, with small 
numbers of cases occurring each year, whereas large and explo-
sive periodic outbreaks may occur in urban areas. 13, 34, 37– 40 The 
finding of anti-CHIKV antibodies in 30–100% of the popula-
tion in some studies suggests asymptomatic or mild infection 
to be frequent, although underdeveloped surveillance systems 
to detect and diagnose cases most certainly contribute to this 
finding and interpretation. 34, 35 
 We found one confirmed case of DENV in Guinea, the 
first human case to be reported from that country, although 
DENV-2 was isolated from a mosquito in 1996. 12 The volume 
of serum was insufficient to perform further testing to iden-
tify the specific infecting DENV serotype. Further evidence 
that DENV circulates in Guinea comes from a 1-month pilot 
study that we conducted in N’Zérékoré in 2004 in which 3 of 
13 (23%) febrile patients tested positive for anti-DENV IgM 
antibody, whereas IgG antibody to DENV was found in 34 
of 261 (13%) convenience samples using the PanBio assays. 
Furthermore, only two of eight (25%) persons in the study 
known to be previously vaccinated against YFV tested IgG 
antibody positive for DENV, suggesting that YFV cross-reac-
tion did not account for the majority of the positive results. 
 DENV-1, -2, and -4 have been repeatedly isolated from 
humans and mosquitoes in various countries of West Africa, 
including Nigeria, Senegal, and Côte d’Ivoire, although 
DENV-3 has been recently reported in Cape Verde and iso-
lated in travelers returning from Senegal and Côte d’Ivoire. 41– 51 
Reports of cases of dengue fever in Africa have increased over 
the past two decades, although the dramatic epidemics seen 
in other parts of the world have not occurred. 52, 53 All four 
serotypes have been found in sub-Saharan Africa, although 
dengue hemorrhagic fever has only been reported in a few 
isolated cases. 52, 53 Recently, it has been proposed that African 
sylvatic DENV strains are less virulent than strains circulat-
ing in other parts of the world and therefore, would not cause 
severe human disease. 54, 55 
 WNV was the most common arbovirus infection noted in 
our study. WNV was reportedly isolated from a wild rodent 
in Guinea in 2006, but this is the first report of human infec-
tion. 32 Serological evidence of WNV infection in humans, 
horses, birds, and arthropods has been reported in neighbor-
ing Senegal and Cote d’Ivoire as well as in one confirmed case 
in a traveler returning from Senegal. 56– 60 
 TAHV is widely distributed in Europe and Asia but has not 
been thoroughly investigated in Africa. Serological evidence 
of human infection in Cameroon and small- mammal infection 
in Tunisia 62 has been reported. 61 To our knowledge, this is the 
first report of symptomatic TAHV infection in Africa. 
 Our study had several limitations. The various impediments 
imposed by the civil unrest in Guinea are described above. 
The possibility that the blood samples could contain Lassa 
virus necessitated heat inactivation, precluding any attempts 
at virus isolation, the gold standard and definitive evidence 
of arbovirus infection, or polymerase chain reaction (PCR). 
Frequent power outages posed a challenge to maintaining the 
cold chain, properly storing specimens and reagents, and per-
forming the onsite serological tests. This perhaps accounts for 
the discrepancy between the negative findings in Guinea and 
the frequent positives found at CDC. Furthermore, the circu-
itous shipment of the serum specimens to the United States 
through Sierra Leone and Cote d’Ivoire resulted in numerous 
breaks in the cold chain, which ultimately precluded all but 
serological diagnosis and could have even resulted in deterio-
ration of antibodies measured through these tests. However, if 
that were the case, our results represent an underestimate of 
the incidence of arbovirus infections in Guinea. It must also be 
noted that cross-reactions are always a potential issue in the 
serological diagnosis of arbovirus infections, although the con-
servative interpretation of the PRNTs performed in this study 
should limit any undue conclusions regarding the specific virus 
infections. Furthermore, even if cross-reactions result in errors 
identifying the specific infecting virus, the important conclu-
sion that many arboviruses are circulating in the area remains 
valid. Lastly, we were not able to make detailed clinical obser-
vations of the patients, test for coinfections, or completely 
exclude the possibility of drug-resistant malarial or bacterial 
infections. 
 The results of our study should serve as a reminder to clini-
cians in Guinea that arboviruses are a frequent cause of febrile 
disease in that country and likely, the rest of West Africa as 
well. More intensive surveillance systems are needed to define 
the scope of the problem, but it can safely be assumed to be 
large. Improving laboratory capacity in sub-Saharan Africa for 
the diagnosis of arbovirus infections will be integral to a full 
understanding of the burden posed by these agents. 
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